Literature DB >> 25921668

Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.

Mazen Noureddin1, Mary E Rinella2.   

Abstract

Diabetes and obesity are associated with nonalcoholic fatty liver disease (NAFLD) and an increased incidence of hepatocellular carcinoma (HCC). NAFLD is the commonest cause of chronic liver disease. HCC can develop in NAFLD patients even without cirrhosis, suggesting an association between the metabolic process and HCC and raising a concern that many cancers could be missed given high NAFLD prevalence and screening limitations. The increasing prevalence of these conditions and lack of effective treatments necessitate a better understanding of their connection. This article defines the known interrelationships and common pathways between NAFLD, diabetes, obesity and HCC and possible chemoprevention strategies.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemoprevention; Cirrhosis; Diabetes; Hepatocellular carcinoma; Insulin resistance; Nonalcoholic steatohepatitis; Noncirrhotic; Obesity

Mesh:

Substances:

Year:  2015        PMID: 25921668      PMCID: PMC6658171          DOI: 10.1016/j.cld.2015.01.012

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  51 in total

1.  Association of Adiponectin gene polymorphisms and nonalcoholic fatty liver disease.

Authors:  Hong-Jue Li; Chang-Ping Li; Chao Zhang; Xiao-Lin Zhong; Lei Shi
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  High protein/fish oil diet prevents hepatic steatosis in NONcNZO10 mice; association with diet/genetics-regulated micro-RNAs.

Authors:  Nikhil Adi; Jennipher Adi; Roberta Marques Lassance-Soares; Paul Kurlansky; Hong Yu; Keith A Webster
Journal:  J Diabetes Metab       Date:  2016-06-16

Review 3.  Therapeutic pipeline in nonalcoholic steatohepatitis.

Authors:  Raj Vuppalanchi; Mazen Noureddin; Naim Alkhouri; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-10       Impact factor: 46.802

Review 4.  Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease.

Authors:  Alessandro Mantovani; Giovanni Targher
Journal:  Ann Transl Med       Date:  2017-07

5.  Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.

Authors:  Jeffrey Cui; Len Philo; Phirum Nguyen; Heather Hofflich; Carolyn Hernandez; Ricki Bettencourt; Lisa Richards; Joanie Salotti; Archana Bhatt; Jonathan Hooker; William Haufe; Catherine Hooker; David A Brenner; Claude B Sirlin; Rohit Loomba
Journal:  J Hepatol       Date:  2016-05-02       Impact factor: 25.083

6.  High fat diet and exercise lead to a disrupted and pathogenic DNA methylome in mouse liver.

Authors:  Dan Zhou; Ryan A Hlady; Marissa J Schafer; Thomas A White; Chen Liu; Jeong-Hyeon Choi; Jordan D Miller; Lewis R Roberts; Nathan K LeBrasseur; Keith D Robertson
Journal:  Epigenetics       Date:  2016-11-18       Impact factor: 4.528

7.  Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care.

Authors:  Brian McMahon; Joan Block; Timothy Block; Chari Cohen; Alison A Evans; Anu Hosangadi; W Thomas London; Morris Sherman
Journal:  J Natl Cancer Inst       Date:  2015-11-30       Impact factor: 13.506

8.  Inhibition of pancreatic lipase by black tea theaflavins: Comparative enzymology and in silico modeling studies.

Authors:  Shannon L Glisan; Kimberly A Grove; Neela H Yennawar; Joshua D Lambert
Journal:  Food Chem       Date:  2016-08-18       Impact factor: 7.514

9.  The Morbidity and Comorbidity of Nonalcoholic Fatty Liver Disease and Different Glucose Intolerance Strata in a Community-Based Chinese Population.

Authors:  Xiuying Zhang; Xianghai Zhou; Xueyao Han; Zuodi Fu; Lianying Wang; Yufeng Li; Linong Ji
Journal:  Metab Syndr Relat Disord       Date:  2020-05-27       Impact factor: 1.894

10.  Molecular classification of hepatocellular carcinoma: potential therapeutic implications.

Authors:  Nicolas Goossens; Xiaochen Sun; Yujin Hoshida
Journal:  Hepat Oncol       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.